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The Evaluation of Essential Oils for Antimicrobial Activity 
Abstract 
The emergence of antibiotic resistant bacteria is of pressing concern as health care 
associated infections kill 99,000 people a year in the U.S. alone.  Researchers are currently 
looking for new antibiotics in alternative sources.  Essential oils are traditionally known to have 
medical benefits, and cinnamon, tea tree, and eucalyptus oils have shown antibiotic activity.  
Initial testing via standard microbiological protocols found minimum inhibitory concentration 
(MIC) values of 0.039% for cinnamon, 1.25% for tea tree, and 0.313% for eucalyptus.  All three 
oils proved effective against both Gram-positive and Gram-negative bacteria.  Cinnamon bark 
oil, Cinnamomum cassia Blume, appeared most effective.  More thorough microbiological 
analysis revealed it to be bactericidal and retained antibacterial activity in the presence of human 
serum protein.  The results revealed cinnamon bark oil may contain a promising novel antibiotic. 
Introduction 
Infectious diseases, particularly those caused by bacterial microorganisms, are still 
among the top causes of mortality in the world.  The rate of infections caused by bacteria that 
have acquired antibiotic resistance is a staggering proportion.  This is especially concerning in 
hospital settings where 1.7 million health care-associated infections are acquired and kill 99,000 
people every year.  It is estimated that these infections cause between $28 and $32 billion dollars 
to the health care industry (5).  Several resistant strains, such as multi-antibiotic resistant 
Staphylococcus aureus (MRSA), carbapenem resistant enterobacteriaceae (CRE), Vancomycin 
Resistant Enterococci (VRE), and antibiotic resistant hypervariant Clostridium difficile (Cdiff), 
are commonly acquired through a nosocomial infection and demonstrate the necessity of novel 
antibiotics to combat bacteria that have become resistant to currently used antibiotics. 
Bacteria can become resistant to antibiotics in a number of ways, one of which is random 
mutation.  Mutations can occur in DNA which would usually code for antibiotic sensitivity and 
in turn code for resistance (9).  Once this occurs, the bacterium can spread the mutation when it 
produces daughter cells (9).  This mutation occurs in about one per million to one per billion 
cells (9).  Another mode by which bacteria can become resistant is by the transfer of plasmids 
that code for resistance from one cell to another through conjugation.  For either circumstance, 
once one bacterium becomes resistant, the number of resistant bacteria will begin to increase (9).  
There has been much concern in recent years over the misuse and overuse of antibiotics.  Misuse 
can occur with the prescription of antibiotics when they are not necessary, and some worry 
antibiotics are being overused in the agriculture and livestock business where recommended 
doses are commonly added to feed for health purposes and increased rates of livestock growth 
(9).  When this occurs, resistant bacteria survive and are artificially selected for and allowed to 
replicate.  This can lead to rapid growth of resistant bacteria which are resistant to current 
antibiotics.  There are few treatments currently available that can combat these antibiotic 
resistant bacteria, and the necessity of novel antibiotics is becoming evident. 
Unfortunately, progress in the development of new antibiotics has tapered off as several 
large pharmaceutical companies have decreased their infectious disease discovery programs.  
Much of the current research is looking toward synthesizing novel derivatives which are 
modeled after current antibiotics (11).  There has been low success rates in finding novel 
antibiotics with these derivatives, and this could be because a majority of the antibiotics used 
today are produced naturally from soil streptomycetes and fungi (11).  While many large 
companies are focusing on manmade products, and finding little success, some researchers are 
once again looking toward natural sources for new and improved antibiotics (11).  One natural 
product, which has been around for thousands of years, may hold the key to finding new 
antibiotics: essential oils derived from plants.  
EOs are aromatic liquids generally made through a steam distillation process of plant 
material which can be traced back over 2000 years to Egyptian, Persian and Indian roots; but can 
also be made through extraction, enfleurage, fermentation and  expression (2).  EOs are typically 
made from aromatic plants of warm, tropical regions and can be made from nearly any plant 
organ, such as leaves, bark, herbs, roots, seeds, stems, and fruits.  Climate, soil, plant organ, age 
of plant, and harvest time all affect the quality and quantity of an essential oil yield (1).  EOs 
have been used for pharmaceutical purposes since the 13th century in some areas of Europe (7), 
but their use was not widespread until they were traded in London in the 16th century (2).  French 
physician, Du Chesne, noted that by the 17th century, EOs were a common medical practice in 
Europe, with pharmacies stocking 15 to 20 different essential oils at a time (7).  It was not until 
1881 that EOs were tested for antimicrobial properties, when De La Croix examined vapors (2).  
By the 19th and 20th centuries, EOs were increasingly used for fragrances and flavoring different 
foods (7). 
Today, only a small percentage of the essential oils created are used for aromatherapy.  
EOs have countless uses, such as perfumes, cosmetics, dentistry, food preservatives and 
flavoring, and more (1).  In recent years, more research has been done to determine the 
antimicrobial nature of numerous EOs against different bacteria (1, 7).  Essential oils have also 
been found to have antiviral, antiparasitic, insecticidal, antitoxigenic, antiseptic, and tumor 
inhibiting activities as well (1, 2, 10).  Because EOs are made from various plant components, it 
stands to reason that they would contain properties that the plant uses to protect itself from 
bacteria, viruses, and unwanted insects, while containing fragrances that could help attract 
insects that would be beneficial for pollination (1).  Studies show EOs have the potential to solve 
a variety of different medical problems, including the crisis of antibiotic resistance of infectious 
bacteria. 
We initially tested several essential oils using the Agar Disk Diffusion Test, or the Zone 
of Inhibition Test, to determine if the oil had any antibiotic activity.  If an oil demonstrated a 
promising zone, further testing for Minimum Inhibitory Concentrations (MICs) were performed 
against Staphylococcus aureus and Escherichia coli.  Cinnamon bark oil showed a very low 
MIC, meaning that it remained effective in small doses, and was tested using a Time Kill 
experiment to determine if it is bacteriostatic or bactericidal.  
 
Methods 
Essential Oils 
 The essential oils tested were from a variety of different brands.  The following oils were 
Plant Therapy brand: pine (Pinus Sylvestris), cinnamon bark (Cinnamomum cassia Blume), 
spearmint (Mentha spicata), peppermint (Mentha piperita), and juniper berry (Juniperus 
communis).  Lavender (Lavandula officinalis) and ginger (Zingiber officianale) were Now 
Essential Oils. Orange oil was of the brand LorAnn Oils.  The tea tree (Melaleuca alternifela), 
eucalyptus oils tested were Sundown Naturals and Aura Cacia, respectively. 
 
Anthranilic Acid Derivative- GV-2 
GV-2 was prepared by the Chemistry Department at GVSU and identified using 
analytical (C, H, N) and spectral (IR, HNMR, CNMR, Mass) data.  GV-2 shows antimicrobial 
activity against Gram-positive bacteria, but is not effective against those that are Gram-negative.  
GV-2 is used as a positive control against Staphylococcus aureus and a negative control against 
Escherichia coli for this reason.  GV-2 has an MIC value of 16.0 µg/mL against S. aureus, but this 
value increases in the presence of Human Serum Protein to 128 µg/mL. 
 
Zone Of Inhibition Test 
Initial testing to determine antimicrobial activity of the test compounds was by the zone 
of inhibition test, or agar disc diffusion method (4).  The zone of inhibition test, begins by 
swabbing a plate with overnight cultures of Staphylococcus aureus and Escherichia coli to create 
a “lawn.” Five microliters of essential oil were pipetted onto 6 millimeter sterile paper disks 
which were placed atop the bacterial “lawn” and incubated for 18-24 hours at 37oC.  Areas of 
clearing, or zones of inhibition, around the disks after incubation are measured and indicate that 
the compound has some antimicrobial activity.  Diameter of zones of inhibition were measured 
in millimeters and recorded.  
 
Determination of MIC 
The MIC’s of the tested essential oils were determined by the Clinical Laboratory 
Standards Institute’s method of broth microdilution (3).  The MIC’s were determined by 
inoculation of serial dilutions of the essential oil being tested in Mueller-Hinton broth with S. 
aureus or E. coli.  Cultures were incubated at 37oC for 18-24 hours. If appropriate, 100% Human 
Serum was added to a final concentration of 10%. 
 
Time Kill 
The Time Kill Assay performed on Cinnamon Oil used a solution of four or eight times 
the MIC of the essential oil.  The solution contained final concentrations of 10% test compound, 
80% Mueller-Hinton broth, and 10% inoculum.  Inoculum was created by diluting a 0.5 
Macfarland 1:20.  Growth controls of 9.68% and 4.84% DMSO were utilized to mimic the 
DMSO concentrations in the Cinnamon 8X and 4X tubes, respectively.  Solutions are allowed to 
incubate for 24 hours with one hundred microliter samples taken initially (0 hours), and at 3, 6, 
and 24 hours after inoculation. Samples are serially diluted and plated in duplicate to determine 
the number of colony-forming-units per mL (CFU/mL) at the given sample time. 
 
Results and Discussion 
 Initial testing of the EOs using the agar disk diffusion method resulted in zones of 
clearance, or no growth, listed in table 1.  Cinnamon bark and eucalyptus had the largest zones 
on S. aureus with zones of 27.5 and 19.5 mm, respectively, and were comparable to our positive 
control, GV-2, which measured 26.2 mm in diameter.  Peppermint and spearmint also had large 
zones against S. aureus, 19.5 and 28.0 mm respectively. They were not subjected to further 
testing because of the growth of mutant colonies within the zone of clearance, peppermint on E. 
coli and spearmint on S. aureus (data not shown).  The presence of mutant colony growth 
suggests that it is fairly easy for S. aureus or E. coli to resist either peppermint or spearmint, and 
thus there was no further interest in the two EOs as antibiotics.   
MIC values against S. aureus were determined for cinnamon bark, eucalyptus, and tea 
tree oils; 0.04%, 0.31%, and 1.25% respectively (table 1).  GV-2 has an MIC against S. aureus of 
16.0 µg/mL, but this value increases to 128.0 µg/mL in the presence of 10% Human Serum 
Protein (HSP).  Since cinnamon bark oil had the lowest MIC, we tested its activity in the 
presence of HSP, and it retained the MIC of 0.04%.  GV-2, as well as numerous other 
compounds, bind to HSP, and thus more of the compound must be used in order to inhibit 
bacterial growth.  Binding to HSP can cause concern when considering these compounds as 
medication because the desired effective concentration is very low, as it will be less toxic to the 
body.  Because cinnamon bark oil retains its MIC in the presence of HSP, lower concentrations 
could be used for medicinal purposes when it could be subjected to HSP in the bloodstream. 
 
 Chemical 
Name 
Zone of 
Inhibition 
on  
S. aureus 
(mm) 
Zone of 
Inhibition 
on E. coli 
(mm) 
MIC 
against  
S. aureus 
MIC against  
S. aureus with 
10% Human 
Serum Protein 
MIC 
against 
E. coli 
MIC against 
E. coli with 
10% Human 
Serum 
Protein 
Cinnamon 
Bark 
27.5 12.5 0.04% 0.04% 0.04% 0.04% 
Eucalyptus 19.5 15.5 0.31% --- 0.31% --- 
Tea Tree 13.7 15.7 1.25% --- --- --- 
GV-2 26.2 0.0 16.0 µg/mL 128.0 µg/mL --- --- 
Peppermint 19.5 8.7 --- --- --- --- 
Pine 6.7 7.2 --- --- --- --- 
Lavender 13.0 8.0 --- --- --- --- 
Spearmint 28.0 9.0 --- --- --- --- 
Ginger 9.5 0.0 --- --- --- --- 
Juniper 
Berry 
14.5 0.0 --- --- --- --- 
Table 1. Zone of Inhibition (diameter), and MIC values (percentage of oil and µg/mL for GV-2) of several essential 
oils and synthesized compounds. Dashes indicate no testing of the compounds. 
 
 A time kill assay was performed to determine if cinnamon bark oil kills bacteria or 
inhibits its growth.  The values of table 2, reported in log10 Colony Forming Units (CFU) per 
milliliter, depict the increase of bacterial growth that would be expected at each of the sampling 
times.  The concentrations of the growth control, 9.68% and 4.84% DMSO, match those of the 
cinnamon ark Oil at 8X and 4X the MIC.  This allows for better comparison of growth between 
the control and the cinnamon bark oil.  The growth control also depicts that DMSO is not 
responsible for the decrease in bacteria after incubation as the CFU/mL increases over time.  A 3 
log10 decrease or greater in bacteria when subtracting the count at 0 hours from 24 hours 
constitutes the test compound as bactericidal (14).  If the difference is less than a 3 log10, this 
suggests bacteriostatic (14).  According to the summarized results of the time kill (table 3), GV-
2, a known bacteriostatic compound, registered a 0.4 log10 and 2.7 log10 decrease in CFU/mL for 
4X and 8X times the MIC, respectively, which falls in the given parameter to be determined 
bacteriostatic.   
Cinnamon bark oil had a 3.6 log10 decrease in bacteria at a concentration of 4X the MIC 
after 24 hours of incubation.  The results for 8X the MIC are recorded as ND in tables 2 and 3 
because there was no growth detected from undiluted samples.  This indicates that the cinnamon 
bark oil killed such a great number of bacteria that they were virtually undetectable at the 3, 6 
and 24 hour tubes, when the results for other concentrations and compounds needed to be diluted 
in order to be counted.  Because there was no growth, no proper log10 value could be associated 
with the sample, yet these results conclude that the cinnamon bark oil is bactericidal.  The 
experiment was repeated with only cinnamon at 8X the MIC, and the results were consistent with 
the original experiment.  
 
Time Point 
(hours) 
Growth 
Control 
9.68% 
DMSO 
Growth 
Control 
4.84% 
DMSO 
Cinnamon 
Bark Oil 
8X MIC 
0.32% 
Cinnamon 
Bark Oil 
4X MIC 
0.16% 
GV-2  
8X MIC 
128 µg/mL 
GV-2  
4X MIC  
64 µg/mL 
0 5.4 5.7 5.4 5.6 5.7 5.6 
3 6.2 6.6 ND 4.7 4.9 5.2 
6 7.0 7.8 ND 4.1 4.9 5.3 
24 8.8 8.9 ND 2 3.0 5.2 
Table 2. Time Kill Experiment summary of the antibacterial activity of cinnamon bark oil and a comparator agent 
(GV-2) versus Staphylococcus aureus.  Results shown are reported as log10 colony forming units (CFU) per 
milliliter.  Samples were taken at 0, 3, 6, and 24 hours to determine the CFU in solution at each time point.  A result 
of “ND” indicates that there was no detectable growth from the sample.  
 
Antibacterial Agent Concentration (Fold-
MIC) 
Maximal kill at any 
time point 
Bacterial kill at 24 
hours 
Cinnamon Bark Oil 0.32% (8X) ND ND 
Cinnamon Bark Oil 0.16% (4X) -3.6 -3.6 
GV-2 128.0 µg/mL (8X) -2.7 -2.7 
GV-2 64.0 µg/mL (4X) -0.4 -0.4 
Table 3. Summarized Time-kill results for cinnamon bark oil and GV-2. Maximal Kill and Kill after 24 hours 
determined by Bacterial count after incubation minus the initial inoculum.  A negative value indicates a net kill and 
a positive value indicates a net growth. Results of the time kill are reported as log10 CFU/mL.  A result of “ND” 
indicates that there was no detectable growth from the sample. 
 
 Having a bactericidal quality can be useful when understanding how a compound 
interacts with the bacteria it is targeting.  Because it is killing bacteria, there may be some 
concern that cinnamon bark oil could have some toxic effect for human cells.  Cinnamon bark oil 
has been used for years to add flavor, and as a health preventative measure for different types of 
animals, such as lactating sows and small piglets, indicating that it does not appear to be toxic in 
minimal doses (2).  Cytotoxicity tests have been run on various cinnamon oils, including 
Cinnamomum zeylancium (6, 13), and Cinnamomum cassia Blume.  Fabio et al. tested the 
cytotoxicity of several essential oils, and could not determine if cinnamon oil’s (Cinnamomum 
zeylancium) antimicrobial activity was due to cytotoxicity, as the MIC was higher than the 
highest minimum nontoxic concentration (6).  On the other hand, Ooi et al. concluded that 
Cinnamomum zeylancium inhibited cell growth of rat fibroblast cells in a concentration 
dependent matter, but did not show cytotoxicity in a time dependent-matter (13).    
While it may not be logical to distribute cinnamon bark oil as an antibiotic, one of its 
constituents may have antibacterial properties from which an antibiotic could be derived.  
Researchers have determined that cinnamon bark oil (Cinnamomum cassia Blume) is largely 
composed of trans-cinnamaldehyde, approximately 85%, and nearly 9% o-methoxy-
cinnamaldehyde (12).  When comparing the microbial activity of cinnamon bark oil to its major 
component, cinnamaldehyde, results showed nearly the same activity for both (12).  As 
cinnamon bark oil showed promising results in the Zone and MIC tests, one next step in research 
may be to investigate the individual components of the oil for antimicrobial activity.  Further 
testing on trans-cinnamaldehyde and o-methoxy-cinnamaldehyde of Cinnamomum cassia Blume 
(12) and Cinnamomum zelanicum, (7); and cinnmyl cinnamate, and benzyl cinnamate of 
Cinnamomum zelanicum (7) to determine MICs and cytotoxicity are worthwhile in the pursuit of 
novel antibiotics. 
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